NASDAQ:CTCX Carmell (CTCX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CTCX Stock Alerts $2.09 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.09▼$2.0950-Day Range$1.98▼$3.6652-Week Range$1.70▼$13.31Volume1,559 shsAverage Volume6,696 shsMarket Capitalization$40.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Carmell alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Carmell Stock (NASDAQ:CTCX)Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Its microemulsion formulations do not utilize mineral or vegetable oils and are designed to be non-comedogenic. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics for all fields of use. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Read More CTCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTCX Stock News HeadlinesApril 27, 2024 | americanbankingnews.comShort Interest in Carmell Co. (NASDAQ:CTCX) Increases By 64.3%April 24, 2024 | americanbankingnews.comCarmell (NASDAQ:CTCX) Shares Up 6.3%April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 11, 2024 | globenewswire.comCarmell Announces Successful Closing of $3.0 Million Private PlacementApril 4, 2024 | globenewswire.comCarmell Announces $3.0 Million Private PlacementMarch 27, 2024 | globenewswire.comCarmell Announces Successful Closing of Axolotl Biologix Sale TransactionMarch 22, 2024 | investing.comCarmell Corporation divests subsidiary to focus on skincareMarch 20, 2024 | globenewswire.comCarmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix SubsidiaryApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 18, 2024 | globenewswire.comCarmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics FieldFebruary 28, 2024 | morningstar.comCarmell Corp Ordinary Shares - Class AFebruary 26, 2024 | msn.comWhy Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionFebruary 26, 2024 | globenewswire.comCarmell Announces Product Development Completed for G.L.E.E. Launch in March 2024January 6, 2024 | nasdaq.comCarmell Corporation Common Stock (CTCX)December 9, 2023 | morningstar.comCarmell Corp Ordinary Shares - Class A CTCXNovember 29, 2023 | msn.comCarmell CEO buys shares worth over $15.5k - filingNovember 16, 2023 | finance.yahoo.comCarmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of DirectorsSeptember 12, 2023 | finance.yahoo.comMoonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative MedicineSeptember 5, 2023 | finance.yahoo.comCarmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on AestheticsAugust 19, 2023 | seekingalpha.comCTCX Carmell Therapeutics CorporationAugust 9, 2023 | finance.yahoo.comCarmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand IdentityAugust 6, 2023 | ca.finance.yahoo.comCarmell Therapeutics Corporation (CTCX)August 1, 2023 | morningstar.comCarmell Therapeutics Corp Ordinary Shares - Class AJuly 28, 2023 | barrons.comCarmell Therapeutics Corp.July 28, 2023 | msn.comCarmell jumps on deal to merge with Axolotl BiologixSee More Headlines Receive CTCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carmell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTCX CUSIPN/A CIK1842939 Webwww.carmellrx.com Phone412-894-8248FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,440,000.00 Net MarginsN/A Pretax Margin-327.58% Return on Equity-154.49% Return on Assets-13.94% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book1.95Miscellaneous Outstanding Shares19,250,000Free FloatN/AMarket Cap$40.23 million OptionableNot Optionable Beta0.32 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Rajiv Sarman Shukla (Age 49)Executive Chairman & CEO Dr. Phil Campbell Ph.D.Founder and Chief Scientific OfficerDr. Lee Weiss Ph.D.FounderDr. James Burgess M.D.FounderBryan J. CassadayChief Financial OfficerKey CompetitorsLucid DiagnosticsNASDAQ:LUCDLENSARNASDAQ:LNSRCo-DiagnosticsNASDAQ:CODXModular MedicalNASDAQ:MODDDarioHealthNASDAQ:DRIOView All CompetitorsInsiders & InstitutionsHubbell Strickland Wealth Management LLCBought 12,548 shares on 4/18/2024Ownership: 0.065%Gilles SpenlehauerBought 313 shares on 12/14/2023Total: $1,129.93 ($3.61/share)Richard A UptonBought 2,000 shares on 12/12/2023Total: $7,000.00 ($3.50/share)Scott M FrischBought 199 shares on 12/7/2023Total: $610.93 ($3.07/share)Scott M FrischBought 277 shares on 12/5/2023Total: $858.70 ($3.10/share)View All Insider TransactionsView All Institutional Transactions CTCX Stock Analysis - Frequently Asked Questions How have CTCX shares performed in 2024? Carmell's stock was trading at $3.81 at the start of the year. Since then, CTCX shares have decreased by 45.1% and is now trading at $2.09. View the best growth stocks for 2024 here. Are investors shorting Carmell? Carmell saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 23,500 shares, an increase of 64.3% from the March 31st total of 14,300 shares. Based on an average trading volume of 6,200 shares, the short-interest ratio is currently 3.8 days. Currently, 0.2% of the shares of the company are short sold. View Carmell's Short Interest. When is Carmell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our CTCX earnings forecast. Who are Carmell's major shareholders? Carmell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hubbell Strickland Wealth Management LLC (0.07%). Insiders that own company stock include Bryan J Cassaday, Gilles Spenlehauer, Rajiv Shukla, Randolph W Hubbell, Richard A Upton and Scott M Frisch. View institutional ownership trends. How do I buy shares of Carmell? Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTCX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
